Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Shares Issued (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Shares Issued for 6 consecutive years, with $73000.0 as the latest value for Q4 2025.

  • Quarterly Shares Issued rose 105.45% to $73000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$32.7 million through Dec 2025, down 9927.33% year-over-year, with the annual reading at $264000.0 for FY2025, 20.72% down from the prior year.
  • Shares Issued for Q4 2025 was $73000.0 at TScan Therapeutics, up from -$1.3 million in the prior quarter.
  • The five-year high for Shares Issued was $89.5 million in Q4 2021, with the low at -$49.9 million in Q4 2023.
  • Average Shares Issued over 5 years is $6.0 million, with a median of $62000.0 recorded in 2021.
  • Peak annual rise in Shares Issued hit 994260.0% in 2023, while the deepest fall reached 554588.89% in 2023.
  • Over 5 years, Shares Issued stood at $89.5 million in 2021, then tumbled by 99.99% to $9000.0 in 2022, then plummeted by 554588.89% to -$49.9 million in 2023, then surged by 97.32% to -$1.3 million in 2024, then skyrocketed by 105.45% to $73000.0 in 2025.
  • According to Business Quant data, Shares Issued over the past three periods came in at $73000.0, -$1.3 million, and -$31.5 million for Q4 2025, Q4 2024, and Q3 2024 respectively.